Sequenom (SQNM) surged 9.4% today after a Wedbush analyst said results for its Maternit21 fetal...

|By:, SA News Editor

Sequenom (SQNM) surged 9.4% today after a Wedbush analyst said results for its Maternit21 fetal genetic tests make it harder to argue that investors should short the stock. “SQNM has effectively met development and commercial launch milestones in the last 12 months and has driven significant test volume in the first six months of launch," the firm says.